Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 23;24(7):6051.
doi: 10.3390/ijms24076051.

Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease

Emanuele Morena  1 , Carmela Romano  2 , Martina Marconi  1 , Selene Diamant  1 , Maria Chiara Buscarinu  1 , Gianmarco Bellucci  1 , Silvia Romano  1 , Daniela Scarabino  3 , Marco Salvetti  1   4 , Giovanni Ristori  1   5
Affiliations
Review

Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease

Emanuele Morena et al. Int J Mol Sci. .

Abstract

Huntington's disease (HD) is characterized by clinical motor impairment (e.g., involuntary movements, poor coordination, parkinsonism), cognitive deficits, and psychiatric symptoms. An inhered expansion of the CAG triplet in the huntingtin gene causing a pathogenic gain-of-function of the mutant huntingtin (mHTT) protein has been identified. In this review, we focus on known biomarkers (e.g., mHTT, neurofilament light chains) and on new biofluid biomarkers that can be quantified in plasma or peripheral blood mononuclear cells from mHTT carriers. Circulating biomarkers may fill current unmet needs in HD management: better stratification of patients amenable to etiologic treatment; the initiation of preventive treatment in premanifest HD; and the identification of peripheral pathogenic central nervous system cascades.

Keywords: DNA damage response; Huntington’s disease; biomarker; blood; gene therapy; leukocyte telomere length; mHTT; manifest; neurofilament light chain; peripheral biomarker; plasma; premanifest.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clinical phases of Huntington’s disease [9].
Figure 2
Figure 2
Biomarkers for Huntington’s disease [23].
See this image and copyright information in PMC

References

    1. Gusella J.F., Wexler N.S., Conneally P.M., Naylor S.L., Anderson M.A., Tanzi R.E., Watkins P.C., Ottina K., Wallace M.R., Sakaguchi A.Y. A Polymorphic DNA Marker Genetically Linked to Huntington’s Disease. Nature. 1983;306:234–238. doi: 10.1038/306234a0. - DOI - PubMed
    1. Ross C.A. When More Is Less: Pathogenesis of Glutamine Repeat Neurodegenerative Diseases. Neuron. 1995;15:493–496. doi: 10.1016/0896-6273(95)90138-8. - DOI - PubMed
    1. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., Barnes G., Taylor S.A., James M., Groot N., et al. A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington’s Disease Chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72:971–983. doi: 10.1016/0092-8674(93)90585-E. - DOI - PubMed
    1. Ross C.A., Tabrizi S.J. Huntington’s Disease: From Molecular Pathogenesis to Clinical Treatment. Lancet Neurol. 2011;10:83–98. doi: 10.1016/S1474-4422(10)70245-3. - DOI - PubMed
    1. Handbook of Clinical Neurology|Huntington Disease|ScienceDirect.Com by Elsevier. [(accessed on 18 August 2022)]. Available online: https://www-sciencedirect-com.ezproxy.uniroma1.it/handbook/handbook-of-c....

MeSH terms